董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Dwight E. Ellingwood | 男 | Director | 70 | 14.85万美元 | 未持股 | 2023-01-27 |
| John C. McIlwraith | 男 | Chairman of the Board | 63 | 14.73万美元 | 未持股 | 2023-01-27 |
| Catherine A. Sazdanoff | 女 | Director | 66 | 15.35万美元 | 未持股 | 2023-01-27 |
| Jack Kenny | 男 | Chief Executive Officer and Director | 54 | 459.88万美元 | 未持股 | 2023-01-27 |
| John M. Rice, Jr. | 男 | Director | 73 | 14.38万美元 | 未持股 | 2023-01-27 |
| Felicia Williams | 女 | Director | 57 | 16.00万美元 | 未持股 | 2023-01-27 |
| James M. Anderson | 男 | Director | 81 | 16.30万美元 | 未持股 | 2023-01-27 |
| Anthony P. Bihl III | 男 | Director | 66 | 15.90万美元 | 未持股 | 2023-01-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jack Kenny | 男 | Chief Executive Officer and Director | 54 | 459.88万美元 | 未持股 | 2023-01-27 |
| Andrew S. Kitzmiller | 男 | Executive Vice President and Chief Financial Officer | 43 | 88.29万美元 | 未持股 | 2023-01-27 |
| Lourdes G. Weltzien | -- | Executive Vice President, Life Science | 57 | 123.40万美元 | 未持股 | 2023-01-27 |
| Tony Serafini Lamanna | 男 | Executive Vice President, Diagnostics | 59 | 119.94万美元 | 未持股 | 2023-01-27 |
| Andrew S. Kitzmiller | 男 | Executive Vice President and Chief Financial Officer | 43 | 未披露 | 未持股 | 2023-01-27 |
董事简历
中英对照 | 中文 | 英文- Dwight E. Ellingwood
-
Dwight E. Ellingwood目前担任俄亥俄州辛辛那提的TriHealth的战略、公关和公共事务部的高级副总裁，他于2014年11月加入TriHealth。就在加入TriHealth前，从2014年1月到2014年11月，Ellingwood先生担任Collective Impact on Health与The Health Collaborative的首席高管。从1997年到2013年，Ellingwood先生担任辛辛那提儿童医学中心（Cincinnati Children’s Hospital Medical Center）的规划和业务开发部的高级副总裁。
Dwight E. Ellingwood,has over 40 years of experience in health care strategy, planning and business development, and since 2017 has served as a Teaching Professor and Associate Director for Practitioner Experience in the Masters Program of the Department of Health Services Administration at Xavier University in Cincinnati, Ohio. Mr. Ellingwood previously served as Senior Vice President of Strategy, Communications and Public Affairs for TriHealth, Inc. in Cincinnati, Ohio (November 2014 – July 2016) and as the Lead Executive for the Collective Impact on Health, The Health Collaborative (2014). From 1997 to 2013, Mr. Ellingwood served as Senior Vice President, Planning and Business Development for Cincinnati Children's Hospital Medical Center, following executive experience with the Spohn Health System in Corpus Christi, Texas (1990 – 1997) and as a health care consultant in Salt Lake City, Utah (1978 – 1990). - Dwight E. Ellingwood目前担任俄亥俄州辛辛那提的TriHealth的战略、公关和公共事务部的高级副总裁，他于2014年11月加入TriHealth。就在加入TriHealth前，从2014年1月到2014年11月，Ellingwood先生担任Collective Impact on Health与The Health Collaborative的首席高管。从1997年到2013年，Ellingwood先生担任辛辛那提儿童医学中心（Cincinnati Children’s Hospital Medical Center）的规划和业务开发部的高级副总裁。
- Dwight E. Ellingwood,has over 40 years of experience in health care strategy, planning and business development, and since 2017 has served as a Teaching Professor and Associate Director for Practitioner Experience in the Masters Program of the Department of Health Services Administration at Xavier University in Cincinnati, Ohio. Mr. Ellingwood previously served as Senior Vice President of Strategy, Communications and Public Affairs for TriHealth, Inc. in Cincinnati, Ohio (November 2014 – July 2016) and as the Lead Executive for the Collective Impact on Health, The Health Collaborative (2014). From 1997 to 2013, Mr. Ellingwood served as Senior Vice President, Planning and Business Development for Cincinnati Children's Hospital Medical Center, following executive experience with the Spohn Health System in Corpus Christi, Texas (1990 – 1997) and as a health care consultant in Salt Lake City, Utah (1978 – 1990).
- John C. McIlwraith
-
John C. McIlwraith，2010年3月，他联合创办Allos Ventures（风险资本公司）。从那时起，他担任董事总经理。创办Allos Ventures之前，他1997年加入Blue Chip Venture Company（总部位于辛辛那提的风险资本和私人股本公司）并曾担任其董事总经理。他曾在多个卫生保健或信息技术公司的董事会任职超过20年。他目前担任Assurex Health, Inc.（精密医药公司，为行为健康状况医疗服务提供者提供治疗决策支持）的首席董事。1997年之前，他担任上市Quantum Health Resources, Inc.的高级副总裁战略规划和总法律顾问， the Jones Day律师事务所合伙人。
John C. McIlwraith,co-founded Allos Ventures, a venture capital firm, in March 2010 and has served as a Managing Director there since that time. Prior to founding Allos Ventures, Mr. McIlwraith was a Managing Director of Blue Chip Venture Company, a Cincinnati-based venture capital firm, which he joined in 1997. He has served on the board of directors of more than 20 health care or information technology companies, including as the Chairman of the Board and later Lead Director of Assurex Health, the provider of a pharmacogenetic test that analyzed genetic variations impacting how patients metabolize and respond to medications that treat mental health conditions, which was sold to Myriad Genetics. Prior to 1997, Mr. McIlwraith served as Senior Vice President of Strategic Planning and General Counsel of publicly traded Quantum Health Resources, Inc., a provider of biologic drugs and other therapies to patients with rare chronic diseases; Senior Vice President of Development of Olsten Health Services (which acquired Quantum); and was a partner in the Jones Day law firm. - John C. McIlwraith，2010年3月，他联合创办Allos Ventures（风险资本公司）。从那时起，他担任董事总经理。创办Allos Ventures之前，他1997年加入Blue Chip Venture Company（总部位于辛辛那提的风险资本和私人股本公司）并曾担任其董事总经理。他曾在多个卫生保健或信息技术公司的董事会任职超过20年。他目前担任Assurex Health, Inc.（精密医药公司，为行为健康状况医疗服务提供者提供治疗决策支持）的首席董事。1997年之前，他担任上市Quantum Health Resources, Inc.的高级副总裁战略规划和总法律顾问， the Jones Day律师事务所合伙人。
- John C. McIlwraith,co-founded Allos Ventures, a venture capital firm, in March 2010 and has served as a Managing Director there since that time. Prior to founding Allos Ventures, Mr. McIlwraith was a Managing Director of Blue Chip Venture Company, a Cincinnati-based venture capital firm, which he joined in 1997. He has served on the board of directors of more than 20 health care or information technology companies, including as the Chairman of the Board and later Lead Director of Assurex Health, the provider of a pharmacogenetic test that analyzed genetic variations impacting how patients metabolize and respond to medications that treat mental health conditions, which was sold to Myriad Genetics. Prior to 1997, Mr. McIlwraith served as Senior Vice President of Strategic Planning and General Counsel of publicly traded Quantum Health Resources, Inc., a provider of biologic drugs and other therapies to patients with rare chronic diseases; Senior Vice President of Development of Olsten Health Services (which acquired Quantum); and was a partner in the Jones Day law firm.
- Catherine A. Sazdanoff
-
Catherine A. Sazdanoff，2015年1月以来，她担任 Sazdanoff Consulting LLC的首席执行官和总裁，专门从事业务发展、管理和战略咨询。此外2015年1月以来，她一直担任mProve Health LLC（位于弗吉尼亚州阿灵顿移动健康科技公司）战略顾。从2006年到2015年，她担任Takeda Pharmaceutical International, Inc. “Takeda”（日本Takeda Pharmaceutical Corporation的全资子公司）许多行政职位，包括副总裁，公司项目主管（2012年-2015年），副总裁，负责全球业务发展（2011年- 2013年）和副总裁，负责企业发展（2010年-2011年）。她在竹田雅培公司（Abbott Laboratories）任职大约22年，她担任许多高管职位。
Catherine A. Sazdanoff,Since 2015, Catherine A. Sazdanoff has served as President and Chief Executive Officer of Sazdanoff Consulting, LLC, providing health care strategy and business development advisory services to a number of clients, including currently serving in the following capacities for Strata Oncology Inc., a precision oncology company: Chief Business Development Officer (since February 2021), and Chief Compliance and Legal Officer (since December 2019). This follows Ms. Sazdanoff having joined Strata in May 2016 as Chief Business Officer (May 2016 – September 2017) and consulted as Business Advisor (October 2017 – February 2019). Since January 2022, Ms. Sazdanoff has also served as an independent director of Vascugen, Inc., a stem-cell research and development company, including having served on a special M&A committee of the board. Ms. Sazdanoff is also faculty since May 2017 with Practicing Law Institute, annually teaching Advanced Licensing in Life Sciences. She was also an independent director of the board of InMed Pharmaceuticals, Inc. (July 2019 – February 2022), having chaired its nominating and governance committee and served on its audit and compensation committees. Previously, Ms. Sazdanoff was a member (April 2016 – December 2022) of the Advisory Board of Neurocern, Inc., a private dementia insuretech company, and a lecturer (March 2018 – July 2021) in the Business of Biotech program at the University of Chicago Graham School for Continuing and Professional Education. Ms. Sazdanoff's prior corporate roles include a number of global corporate positions with Takeda Pharmaceuticals, Inc. ("Takeda"), a wholly-owned subsidiary of Japanese-based Takeda Pharmaceutical Corporation, from 2006 to 2015 including VP, Head of Corporate Projects (2012 – 2015); VP, Global Business Development (2011 – 2013); and VP, Corporate Development (2010 – 2011). Ms. Sazdanoff's time at Takeda was preceded by approximately 22 years with Abbott Laboratories, where she held numerous executive positions covering legal, compliance and business development. - Catherine A. Sazdanoff，2015年1月以来，她担任 Sazdanoff Consulting LLC的首席执行官和总裁，专门从事业务发展、管理和战略咨询。此外2015年1月以来，她一直担任mProve Health LLC（位于弗吉尼亚州阿灵顿移动健康科技公司）战略顾。从2006年到2015年，她担任Takeda Pharmaceutical International, Inc. “Takeda”（日本Takeda Pharmaceutical Corporation的全资子公司）许多行政职位，包括副总裁，公司项目主管（2012年-2015年），副总裁，负责全球业务发展（2011年- 2013年）和副总裁，负责企业发展（2010年-2011年）。她在竹田雅培公司（Abbott Laboratories）任职大约22年，她担任许多高管职位。
- Catherine A. Sazdanoff,Since 2015, Catherine A. Sazdanoff has served as President and Chief Executive Officer of Sazdanoff Consulting, LLC, providing health care strategy and business development advisory services to a number of clients, including currently serving in the following capacities for Strata Oncology Inc., a precision oncology company: Chief Business Development Officer (since February 2021), and Chief Compliance and Legal Officer (since December 2019). This follows Ms. Sazdanoff having joined Strata in May 2016 as Chief Business Officer (May 2016 – September 2017) and consulted as Business Advisor (October 2017 – February 2019). Since January 2022, Ms. Sazdanoff has also served as an independent director of Vascugen, Inc., a stem-cell research and development company, including having served on a special M&A committee of the board. Ms. Sazdanoff is also faculty since May 2017 with Practicing Law Institute, annually teaching Advanced Licensing in Life Sciences. She was also an independent director of the board of InMed Pharmaceuticals, Inc. (July 2019 – February 2022), having chaired its nominating and governance committee and served on its audit and compensation committees. Previously, Ms. Sazdanoff was a member (April 2016 – December 2022) of the Advisory Board of Neurocern, Inc., a private dementia insuretech company, and a lecturer (March 2018 – July 2021) in the Business of Biotech program at the University of Chicago Graham School for Continuing and Professional Education. Ms. Sazdanoff's prior corporate roles include a number of global corporate positions with Takeda Pharmaceuticals, Inc. ("Takeda"), a wholly-owned subsidiary of Japanese-based Takeda Pharmaceutical Corporation, from 2006 to 2015 including VP, Head of Corporate Projects (2012 – 2015); VP, Global Business Development (2011 – 2013); and VP, Corporate Development (2010 – 2011). Ms. Sazdanoff's time at Takeda was preceded by approximately 22 years with Abbott Laboratories, where she held numerous executive positions covering legal, compliance and business development.
- Jack Kenny
-
Jack Kenny担任Meridian的首席执行官，于2017年10月9日加入该公司。在加入Meridian之前，Kenny先生曾于2014年10月至2017年5月在西门子梦百合担任北美高级副总裁兼总经理。2012年6月至2014年10月，Kenny先生担任诊断系统公司Becton Dickinson的Vice President兼美国地区总经理。2012年6月之前，Kenny先生在丹纳赫公司和Quest Diagnostics担任执行职务。
Jack Kenny,has served as a Director of the Company since August 2023. Mr. Kenny is also an independent member of the board of directors for Quantum Si (NASDAQ: QSI), a protein sequencing company, where he has served since May 2023. Mr. Kenny joined Meridian Biosciences ("Meridian"), a life science and diagnostic company, in October 2017, where he served as the Chief Executive Officer and as a member of the board of directors. Mr. Kenny led Meridian's turnaround resulting in the company's sale in January 2023 (to SJL Partners and SD Biosensor). Before his tenure at Meridian, from 2014 to May 2017, Mr. Kenny served as Senior Vice President and General Manager, North America, of Siemens Healthcare, a healthcare company providing healthcare solutions and services. From 2012 to 2014, Mr. Kenny served as Vice President and General Manager, U.S. Region, for Becton Dickinson, a medical device company. Prior to 2012, he held executive roles at Danaher Corporation, a science and technology company, and Quest Diagnostics, a medical laboratory company. Mr. Kenny holds a BS degree from Kettering University. - Jack Kenny担任Meridian的首席执行官，于2017年10月9日加入该公司。在加入Meridian之前，Kenny先生曾于2014年10月至2017年5月在西门子梦百合担任北美高级副总裁兼总经理。2012年6月至2014年10月，Kenny先生担任诊断系统公司Becton Dickinson的Vice President兼美国地区总经理。2012年6月之前，Kenny先生在丹纳赫公司和Quest Diagnostics担任执行职务。
- Jack Kenny,has served as a Director of the Company since August 2023. Mr. Kenny is also an independent member of the board of directors for Quantum Si (NASDAQ: QSI), a protein sequencing company, where he has served since May 2023. Mr. Kenny joined Meridian Biosciences ("Meridian"), a life science and diagnostic company, in October 2017, where he served as the Chief Executive Officer and as a member of the board of directors. Mr. Kenny led Meridian's turnaround resulting in the company's sale in January 2023 (to SJL Partners and SD Biosensor). Before his tenure at Meridian, from 2014 to May 2017, Mr. Kenny served as Senior Vice President and General Manager, North America, of Siemens Healthcare, a healthcare company providing healthcare solutions and services. From 2012 to 2014, Mr. Kenny served as Vice President and General Manager, U.S. Region, for Becton Dickinson, a medical device company. Prior to 2012, he held executive roles at Danaher Corporation, a science and technology company, and Quest Diagnostics, a medical laboratory company. Mr. Kenny holds a BS degree from Kettering University.
- John M. Rice, Jr.
-
JohnM.Rice，Jr.是Cincytech生命科学业务的董事总经理，Cincytech是一家为企业家提供咨询和资本的公司，帮助研究机构通过初创企业将技术商业化，并推动个人和机构向地区公司投资，此前自2014年起担任生命科学总监。Rice博士还是Triathlon Medical Venture Partners（一家风险投资公司，向早期和扩展阶段的生命科学公司投资股权资本）的创始人，曾于2003年至2018年担任管理合伙人。从1989年到2003年，他曾担任SenMed Medical Ventures的董事总经理。在他超过30年的医疗保健风险投资中，Rice博士曾在超过25家私人持有的医疗保健公司的董事会任职，目前担任Genetics，Kurome和Airway Therapeutics的董事会主席。此外，他目前担任the Harrington Discovery Institute的投资顾问委员会主席，并任职Enable Injections公司的董事会。
John M. Rice, Jr. is a Managing Director leading the Life Sciences practice at CincyTech, a firm that provides advice and capital to entrepreneurs, helps research institutions commercialize technology through start-ups, and catalyzes investment from individuals and institutions to regional companies, having previously served as Director of Life Sciences since 2014. Dr. Rice is also the founder of Triathlon Medical Venture Partners, a venture capital firm that invests equity capital in early and expansion stage life science companies, having served as Managing Partner from 2003 - 2018. He was previously a Managing Director at Senmed Medical Ventures from 1989 - 2003. In his greater than 30 years in health care venture capital, Dr. Rice has served on the board of directors of more than 25 privately-held health care companies, currently chairing the boards of Genetesis, Kurome and Airway Therapeutics. In addition, he currently chairs the Investment Advisory Board of the Harrington Discovery Institute and serves on the board of Enable Injections. - JohnM.Rice，Jr.是Cincytech生命科学业务的董事总经理，Cincytech是一家为企业家提供咨询和资本的公司，帮助研究机构通过初创企业将技术商业化，并推动个人和机构向地区公司投资，此前自2014年起担任生命科学总监。Rice博士还是Triathlon Medical Venture Partners（一家风险投资公司，向早期和扩展阶段的生命科学公司投资股权资本）的创始人，曾于2003年至2018年担任管理合伙人。从1989年到2003年，他曾担任SenMed Medical Ventures的董事总经理。在他超过30年的医疗保健风险投资中，Rice博士曾在超过25家私人持有的医疗保健公司的董事会任职，目前担任Genetics，Kurome和Airway Therapeutics的董事会主席。此外，他目前担任the Harrington Discovery Institute的投资顾问委员会主席，并任职Enable Injections公司的董事会。
- John M. Rice, Jr. is a Managing Director leading the Life Sciences practice at CincyTech, a firm that provides advice and capital to entrepreneurs, helps research institutions commercialize technology through start-ups, and catalyzes investment from individuals and institutions to regional companies, having previously served as Director of Life Sciences since 2014. Dr. Rice is also the founder of Triathlon Medical Venture Partners, a venture capital firm that invests equity capital in early and expansion stage life science companies, having served as Managing Partner from 2003 - 2018. He was previously a Managing Director at Senmed Medical Ventures from 1989 - 2003. In his greater than 30 years in health care venture capital, Dr. Rice has served on the board of directors of more than 25 privately-held health care companies, currently chairing the boards of Genetesis, Kurome and Airway Therapeutics. In addition, he currently chairs the Investment Advisory Board of the Harrington Discovery Institute and serves on the board of Enable Injections.
- Felicia Williams
-
Felicia Williams，在多个行业拥有超过30年的审计和公司财务领导经验。自2004年以来，Williams女士一直在Macy's 担任高级领导职务，目前担任高级副总裁，财务和Macy's 首席执行官种族平等行动研究员，这是一个由企业领导的联盟，负责确定和制定公共政策和企业参与解决方案，以解决系统性的种族主义问题。Williams女士于2016年至2020年担任Macy's 执行官，2020年6月至2020年11月担任临时首席财务官，2016年6月至2020年6月担任高级副总裁、财务总监和企业风险官。她曾于2011年2月至2016年6月担任Macy's 财务和风险管理高级副总裁，在此之前，她曾在Macy's 担任多个重要的公司财务职能，包括财务、投资者关系、风险管理、金融服务、财务规划和分析以及内部审计。从1994年到2004年，Williams女士在希腊雅典的the Coca-Cola Hellenic Bottling Company和格鲁吉亚亚特兰大的Coca-Cola Company担任过各种财务职务。在加入Coca-Cola Company之前，Williams曾在Bristol- Myers Squibb和Arthur Andersen & Company工作。Williams女士目前是Anywhere Real Estate Inc.（纽约证券交易所代码：HOUS）的董事会成员和审计委员会主席。Williams女士还在2018年至2023年期间担任Meridian Bioscience，Inc.的董事会成员，包括审计委员会主席。Williams女士在佛罗里达农工大学获得学士学位，是一名注册会计师。
Felicia Williams,holding a BS in Accounting from Florida A&M University and CPA certification. With 30 years of experience, she has held senior finance roles at Macy's including SVP of Finance (2020-2023) and Interim CFO (2020), where she navigated pandemic-era financial challenges. Her career includes key positions at Coca-Cola Hellenic Bottling Company as Chief Audit Executive (2002-2004) and financial leadership roles at The Coca-Cola Company (1994-2002). Ms. Williams currently serves on the boards of Anywhere Real Estate (Audit Chair since 2021) and Neogenomics Laboratories (since 2024). - Felicia Williams，在多个行业拥有超过30年的审计和公司财务领导经验。自2004年以来，Williams女士一直在Macy's 担任高级领导职务，目前担任高级副总裁，财务和Macy's 首席执行官种族平等行动研究员，这是一个由企业领导的联盟，负责确定和制定公共政策和企业参与解决方案，以解决系统性的种族主义问题。Williams女士于2016年至2020年担任Macy's 执行官，2020年6月至2020年11月担任临时首席财务官，2016年6月至2020年6月担任高级副总裁、财务总监和企业风险官。她曾于2011年2月至2016年6月担任Macy's 财务和风险管理高级副总裁，在此之前，她曾在Macy's 担任多个重要的公司财务职能，包括财务、投资者关系、风险管理、金融服务、财务规划和分析以及内部审计。从1994年到2004年，Williams女士在希腊雅典的the Coca-Cola Hellenic Bottling Company和格鲁吉亚亚特兰大的Coca-Cola Company担任过各种财务职务。在加入Coca-Cola Company之前，Williams曾在Bristol- Myers Squibb和Arthur Andersen & Company工作。Williams女士目前是Anywhere Real Estate Inc.（纽约证券交易所代码：HOUS）的董事会成员和审计委员会主席。Williams女士还在2018年至2023年期间担任Meridian Bioscience，Inc.的董事会成员，包括审计委员会主席。Williams女士在佛罗里达农工大学获得学士学位，是一名注册会计师。
- Felicia Williams,holding a BS in Accounting from Florida A&M University and CPA certification. With 30 years of experience, she has held senior finance roles at Macy's including SVP of Finance (2020-2023) and Interim CFO (2020), where she navigated pandemic-era financial challenges. Her career includes key positions at Coca-Cola Hellenic Bottling Company as Chief Audit Executive (2002-2004) and financial leadership roles at The Coca-Cola Company (1994-2002). Ms. Williams currently serves on the boards of Anywhere Real Estate (Audit Chair since 2021) and Neogenomics Laboratories (since 2024).
- James M. Anderson
-
James M. Anderson是提名和企业治理委员会主席。2009年12月31日作为Cincinnati Children’s Hospital Medical Center“CCHMC”的总裁和首席执行官的Anderson先生退休，随后开始担任CCHMC的总裁顾问。Anderson先生自2006年起担任Ameritas Mutual Holding Company董事，他也曾是Federal Reserve Bank of Cleveland的辛辛那提分公司的董事会成员，2012年退休。在加入CCHMC之前，他曾是Taft, Stettinius & Hollister 的一般企业法事业部的合伙人，任职时间24年（1968-1977； 1982-1996）。1977年至1982年他是Xomox Corporation的美国地区运营总裁，该公司是生产特殊程序控制器的上市公司。1997年至2008年他也曾担任Gateway Investment Advisors 的董事。董事会相信Anderson先生的公司法务从业经历以及他在大型医疗机构担任首席执行官的经历使得他对各种企业治理和业务管理事务有着丰富的见解，再加上他是一名独立董事，这些都能让他成为董事会成员。
James M. Anderson,serves as Senior Strategic and External Affairs Advisor with Taft Stettinius & Hollister LLP and President Emeritus of Cincinnati Children's Hospital Medical Center ("CCHMC"), after having served as advisor to the President of CCHMC from January 2010 through June 30, 2017 and as President and Chief Executive Officer of CCHMC from 1996 through 2009. Mr. Anderson serves on the board of managers of CincyTech, a firm that provides advice and capital to entrepreneurs, helps research institutions commercialize technology through startups, and catalyzes investment from individuals and institutions to regional companies. In addition, he serves on the board of directors of Cintrifuse, an organization whose purpose is to stimulate and support the Greater Cincinnati regional start-up community and the connections between start-ups and larger, more established enterprises. From 2006 to 2014, he served as a director of Ameritas Mutual Holding Company and has also served as Chairman of the Board of the Cincinnati Branch of the Federal Reserve Bank of Cleveland, retiring in 2012. Prior to joining the staff of CCHMC, Mr. Anderson was a partner in the general corporate law department at Taft, Stettinius & Hollister for 24 years (1968 – 1977; 1982 – 1996) and president of U.S. operations at Xomox Corporation, a publicly-traded manufacturer of specialty process controls (1977 – 1982), where he also served on the board of directors (1978 – 1980). Mr. Anderson has also served as director of Gateway Investment Advisors (1997 – 2008). - James M. Anderson是提名和企业治理委员会主席。2009年12月31日作为Cincinnati Children’s Hospital Medical Center“CCHMC”的总裁和首席执行官的Anderson先生退休，随后开始担任CCHMC的总裁顾问。Anderson先生自2006年起担任Ameritas Mutual Holding Company董事，他也曾是Federal Reserve Bank of Cleveland的辛辛那提分公司的董事会成员，2012年退休。在加入CCHMC之前，他曾是Taft, Stettinius & Hollister 的一般企业法事业部的合伙人，任职时间24年（1968-1977； 1982-1996）。1977年至1982年他是Xomox Corporation的美国地区运营总裁，该公司是生产特殊程序控制器的上市公司。1997年至2008年他也曾担任Gateway Investment Advisors 的董事。董事会相信Anderson先生的公司法务从业经历以及他在大型医疗机构担任首席执行官的经历使得他对各种企业治理和业务管理事务有着丰富的见解，再加上他是一名独立董事，这些都能让他成为董事会成员。
- James M. Anderson,serves as Senior Strategic and External Affairs Advisor with Taft Stettinius & Hollister LLP and President Emeritus of Cincinnati Children's Hospital Medical Center ("CCHMC"), after having served as advisor to the President of CCHMC from January 2010 through June 30, 2017 and as President and Chief Executive Officer of CCHMC from 1996 through 2009. Mr. Anderson serves on the board of managers of CincyTech, a firm that provides advice and capital to entrepreneurs, helps research institutions commercialize technology through startups, and catalyzes investment from individuals and institutions to regional companies. In addition, he serves on the board of directors of Cintrifuse, an organization whose purpose is to stimulate and support the Greater Cincinnati regional start-up community and the connections between start-ups and larger, more established enterprises. From 2006 to 2014, he served as a director of Ameritas Mutual Holding Company and has also served as Chairman of the Board of the Cincinnati Branch of the Federal Reserve Bank of Cleveland, retiring in 2012. Prior to joining the staff of CCHMC, Mr. Anderson was a partner in the general corporate law department at Taft, Stettinius & Hollister for 24 years (1968 – 1977; 1982 – 1996) and president of U.S. operations at Xomox Corporation, a publicly-traded manufacturer of specialty process controls (1977 – 1982), where he also served on the board of directors (1978 – 1980). Mr. Anderson has also served as director of Gateway Investment Advisors (1997 – 2008).
- Anthony P. Bihl III
-
Anthony P. Bihl III，自2013年12月起担任Bioventus, LLC（该公司开发、生产、并销售骨科治疗产品）的首席执行官兼管理董事会成员。自2011年6月至2012年6月，担任 American Medical Systems（Endo Pharmaceuticals的附属公司）的集团总裁。在此之前，从2008年4月至2011年6月Endo收购AMS，担任AMS的总裁兼首席执行官、董事。从2007年1月到11月，担任Siemens Medical Solutions的诊断部门的首席执行官。从2004年到2006年，担任Bayer HealthCare诊断部门的总裁。在这之前，曾在Bayer HealthCare担任多个业务和财务职位，并在E.I. DuPont工作20年。现任Spectral Diagnostics, Inc.（一家加拿大公司，开发严重败血症及感染性休克的诊断和治疗产品）的董事长、人力资源主席和薪酬委员会主席、审计委员会成员。他是SeraCare Life Sciences Inc.的前董事。
Anthony P. Bihl III,served as Chief Executive Officer and a member of the board of managers of Bioventus, LLC, a company that develops, manufactures and sells products that promote active orthopedic healing, from December 2013 to April 2020. From June 2011 through June 2012, he was Group President of American Medical Systems, or AMS, a subsidiary of Endo Pharmaceuticals. Mr. Bihl was President, Chief Executive Officer and a director of AMS from April 2008 until Endo acquired AMS in June 2011. He served as Chief Executive Officer of the Diagnostics Division of Siemens Medical Solutions from January to November 2007, and as President of the Diagnostics Division of Bayer HealthCare from 2004 through 2006. Prior to that, Mr. Bihl served in a number of operations and finance roles at Bayer HealthCare and for over 20 years at E.I. DuPont. Mr. Bihl is a director and Chairman of the Board of Spectral Medical, Inc. (TSX: EDTXF), a Canadian company that develops products for the diagnosis and treatment of severe sepsis and septic shock, and Sonendo, Inc. (NYSE:SONX), a leading dental technology company. Mr. Bihl previously served on the boards of directors of Flowonix Medical Inc., a privately held company that develops and markets targeted drug delivery platforms (July 2020 – March 2022); Nuvectra Corporation (OTC: NVTRQ) from March 2016 to May 2020; and prior to March 2016, Integer Holdings Corporation (NYSE: ITGR) before it spun off Nuvectra. - Anthony P. Bihl III，自2013年12月起担任Bioventus, LLC（该公司开发、生产、并销售骨科治疗产品）的首席执行官兼管理董事会成员。自2011年6月至2012年6月，担任 American Medical Systems（Endo Pharmaceuticals的附属公司）的集团总裁。在此之前，从2008年4月至2011年6月Endo收购AMS，担任AMS的总裁兼首席执行官、董事。从2007年1月到11月，担任Siemens Medical Solutions的诊断部门的首席执行官。从2004年到2006年，担任Bayer HealthCare诊断部门的总裁。在这之前，曾在Bayer HealthCare担任多个业务和财务职位，并在E.I. DuPont工作20年。现任Spectral Diagnostics, Inc.（一家加拿大公司，开发严重败血症及感染性休克的诊断和治疗产品）的董事长、人力资源主席和薪酬委员会主席、审计委员会成员。他是SeraCare Life Sciences Inc.的前董事。
- Anthony P. Bihl III,served as Chief Executive Officer and a member of the board of managers of Bioventus, LLC, a company that develops, manufactures and sells products that promote active orthopedic healing, from December 2013 to April 2020. From June 2011 through June 2012, he was Group President of American Medical Systems, or AMS, a subsidiary of Endo Pharmaceuticals. Mr. Bihl was President, Chief Executive Officer and a director of AMS from April 2008 until Endo acquired AMS in June 2011. He served as Chief Executive Officer of the Diagnostics Division of Siemens Medical Solutions from January to November 2007, and as President of the Diagnostics Division of Bayer HealthCare from 2004 through 2006. Prior to that, Mr. Bihl served in a number of operations and finance roles at Bayer HealthCare and for over 20 years at E.I. DuPont. Mr. Bihl is a director and Chairman of the Board of Spectral Medical, Inc. (TSX: EDTXF), a Canadian company that develops products for the diagnosis and treatment of severe sepsis and septic shock, and Sonendo, Inc. (NYSE:SONX), a leading dental technology company. Mr. Bihl previously served on the boards of directors of Flowonix Medical Inc., a privately held company that develops and markets targeted drug delivery platforms (July 2020 – March 2022); Nuvectra Corporation (OTC: NVTRQ) from March 2016 to May 2020; and prior to March 2016, Integer Holdings Corporation (NYSE: ITGR) before it spun off Nuvectra.
高管简历
中英对照 | 中文 | 英文- Jack Kenny
Jack Kenny担任Meridian的首席执行官，于2017年10月9日加入该公司。在加入Meridian之前，Kenny先生曾于2014年10月至2017年5月在西门子梦百合担任北美高级副总裁兼总经理。2012年6月至2014年10月，Kenny先生担任诊断系统公司Becton Dickinson的Vice President兼美国地区总经理。2012年6月之前，Kenny先生在丹纳赫公司和Quest Diagnostics担任执行职务。
Jack Kenny,has served as a Director of the Company since August 2023. Mr. Kenny is also an independent member of the board of directors for Quantum Si (NASDAQ: QSI), a protein sequencing company, where he has served since May 2023. Mr. Kenny joined Meridian Biosciences ("Meridian"), a life science and diagnostic company, in October 2017, where he served as the Chief Executive Officer and as a member of the board of directors. Mr. Kenny led Meridian's turnaround resulting in the company's sale in January 2023 (to SJL Partners and SD Biosensor). Before his tenure at Meridian, from 2014 to May 2017, Mr. Kenny served as Senior Vice President and General Manager, North America, of Siemens Healthcare, a healthcare company providing healthcare solutions and services. From 2012 to 2014, Mr. Kenny served as Vice President and General Manager, U.S. Region, for Becton Dickinson, a medical device company. Prior to 2012, he held executive roles at Danaher Corporation, a science and technology company, and Quest Diagnostics, a medical laboratory company. Mr. Kenny holds a BS degree from Kettering University.- Jack Kenny担任Meridian的首席执行官，于2017年10月9日加入该公司。在加入Meridian之前，Kenny先生曾于2014年10月至2017年5月在西门子梦百合担任北美高级副总裁兼总经理。2012年6月至2014年10月，Kenny先生担任诊断系统公司Becton Dickinson的Vice President兼美国地区总经理。2012年6月之前，Kenny先生在丹纳赫公司和Quest Diagnostics担任执行职务。
- Jack Kenny,has served as a Director of the Company since August 2023. Mr. Kenny is also an independent member of the board of directors for Quantum Si (NASDAQ: QSI), a protein sequencing company, where he has served since May 2023. Mr. Kenny joined Meridian Biosciences ("Meridian"), a life science and diagnostic company, in October 2017, where he served as the Chief Executive Officer and as a member of the board of directors. Mr. Kenny led Meridian's turnaround resulting in the company's sale in January 2023 (to SJL Partners and SD Biosensor). Before his tenure at Meridian, from 2014 to May 2017, Mr. Kenny served as Senior Vice President and General Manager, North America, of Siemens Healthcare, a healthcare company providing healthcare solutions and services. From 2012 to 2014, Mr. Kenny served as Vice President and General Manager, U.S. Region, for Becton Dickinson, a medical device company. Prior to 2012, he held executive roles at Danaher Corporation, a science and technology company, and Quest Diagnostics, a medical laboratory company. Mr. Kenny holds a BS degree from Kettering University.
- Andrew S. Kitzmiller
安德鲁·基茨米勒（Andrew S.Kitzmiller）于2019年11月被选为Vice President、首席会计官和财务总监。在此之前，Kitzmiller先生在Milacron HoldingsCorp.（Milacron“；Milacron”；）担任了两年多的高级财务职位，包括Vice President财务和公司财务总监（2019年4月至2019年11月）以及公司财务总监（2017年9月至2019年4月）。在加入Milacron之前，他于2012年12月至2017年11月在通用电气公司（GE”；）的航空航天部门GE Aviation担任了一系列越来越高级的职务。GE的这些职位包括添加剂，航空供应链和工程部门的总监（2016年11月至2017年9月）；卓越会计中心负责人（2014年9月至2016年11月），包括对供应链和工程部门的控制权监督（2016年4月至2016年11月）；以及两个顺序助理财务总监职位。Kitzmiller先生在德勤会计师事务所（Deloitte&Touche LLP）开始他的公共会计职业生涯。
Andrew S. Kitzmiller, was elected Vice President, Chief Accounting Officer, and Controller effective November 2019. Immediately prior, Mr. Kitzmiller served more than two years in senior finance roles at Milacron Holdings Corp. “Milacron”, as Vice President - Finance and Corporate Controller (April 2019 to November 2019) and as Corporate Controller (September 2017 to April 2019). Prior to Milacron, he served in a series of increasingly senior roles at GE Aviation, the aerospace division of General Electric Company (“GE”), from December 2012 through November 2017. These roles at GE included Controller - Additive, Aviation Supply Chain and Engineering Divisions (November 2016 to September 2017); Accounting Center of Excellence Leader (September 2014 to November 2016), including with controllership oversight of the Supply Chain and Engineering Divisions (April 2016 to November 2016); and two sequential assistant controller positions.- 安德鲁·基茨米勒（Andrew S.Kitzmiller）于2019年11月被选为Vice President、首席会计官和财务总监。在此之前，Kitzmiller先生在Milacron HoldingsCorp.（Milacron“；Milacron”；）担任了两年多的高级财务职位，包括Vice President财务和公司财务总监（2019年4月至2019年11月）以及公司财务总监（2017年9月至2019年4月）。在加入Milacron之前，他于2012年12月至2017年11月在通用电气公司（GE”；）的航空航天部门GE Aviation担任了一系列越来越高级的职务。GE的这些职位包括添加剂，航空供应链和工程部门的总监（2016年11月至2017年9月）；卓越会计中心负责人（2014年9月至2016年11月），包括对供应链和工程部门的控制权监督（2016年4月至2016年11月）；以及两个顺序助理财务总监职位。Kitzmiller先生在德勤会计师事务所（Deloitte&Touche LLP）开始他的公共会计职业生涯。
- Andrew S. Kitzmiller, was elected Vice President, Chief Accounting Officer, and Controller effective November 2019. Immediately prior, Mr. Kitzmiller served more than two years in senior finance roles at Milacron Holdings Corp. “Milacron”, as Vice President - Finance and Corporate Controller (April 2019 to November 2019) and as Corporate Controller (September 2017 to April 2019). Prior to Milacron, he served in a series of increasingly senior roles at GE Aviation, the aerospace division of General Electric Company (“GE”), from December 2012 through November 2017. These roles at GE included Controller - Additive, Aviation Supply Chain and Engineering Divisions (November 2016 to September 2017); Accounting Center of Excellence Leader (September 2014 to November 2016), including with controllership oversight of the Supply Chain and Engineering Divisions (April 2016 to November 2016); and two sequential assistant controller positions.
- Lourdes G. Weltzien
Lourdes G.Weltzien于2008年7月加入Meridian，担任生命科学总经理，并于2013年4月被任命为Vice President兼生命科学总经理，于2016年7月被任命为亚太地区市场总裁，并于2018年3月被任命为生命科学执行Vice President。在加入Meridian之前，Weltzien博士自1994年以来在西格玛-奥德里奇公司（现为Millipore-Sigma）担任多个执行和管理职位。
Lourdes G. Weltzien,joined Meridian in July 2008 as General Manager of Life Science and was appointed Vice President and General Manager of Life Science in April 2013, as well as President of Asia Pacific Markets in July 2016, and Executive Vice President, Life Science in March 2018. Prior to joining Meridian, Dr. Weltzien held various executive and management positions with Sigma-Aldrich Corporation (now Millipore-Sigma) since 1994.- Lourdes G.Weltzien于2008年7月加入Meridian，担任生命科学总经理，并于2013年4月被任命为Vice President兼生命科学总经理，于2016年7月被任命为亚太地区市场总裁，并于2018年3月被任命为生命科学执行Vice President。在加入Meridian之前，Weltzien博士自1994年以来在西格玛-奥德里奇公司（现为Millipore-Sigma）担任多个执行和管理职位。
- Lourdes G. Weltzien,joined Meridian in July 2008 as General Manager of Life Science and was appointed Vice President and General Manager of Life Science in April 2013, as well as President of Asia Pacific Markets in July 2016, and Executive Vice President, Life Science in March 2018. Prior to joining Meridian, Dr. Weltzien held various executive and management positions with Sigma-Aldrich Corporation (now Millipore-Sigma) since 1994.
- Tony Serafini Lamanna
托尼·塞拉菲尼·拉马纳（Tony Serafini Lamanna）于2018年4月加入Meridian，担任Vice President兼诊断总经理，并于2020年5月被任命为诊断部门执行Vice President。在加入Meridian之前，Serafini-Lamanna先生自2001年以来一直在西门子梦百合担任多个执行和管理职位。
Tony Serafini Lamanna,joined Meridian in April 2018 as Vice President and General Manager of Diagnostics and was appointed Executive Vice President, Diagnostics in May 2020. Prior to joining Meridian, Mr. Serafini-Lamanna held various executive and management positions with Siemens Healthcare since 2001.- 托尼·塞拉菲尼·拉马纳（Tony Serafini Lamanna）于2018年4月加入Meridian，担任Vice President兼诊断总经理，并于2020年5月被任命为诊断部门执行Vice President。在加入Meridian之前，Serafini-Lamanna先生自2001年以来一直在西门子梦百合担任多个执行和管理职位。
- Tony Serafini Lamanna,joined Meridian in April 2018 as Vice President and General Manager of Diagnostics and was appointed Executive Vice President, Diagnostics in May 2020. Prior to joining Meridian, Mr. Serafini-Lamanna held various executive and management positions with Siemens Healthcare since 2001.
- Andrew S. Kitzmiller
Andrew S. Kitzmiller被任命为Meridian的首席财务官，自2022年2月21日起生效。在加入Meridian之前，Kitzmiller先生自2019年11月起担任Hillenbrand公司副总裁、首席会计干事和财务总监，并在Milacron控股公司担任了两年多的高级财务职务，担任副总裁兼财务和公司财务总监（2019年4月至2019年11月）和公司财务总监（2017年9月至2019年4月）。
Andrew S. Kitzmiller,was appointed as the Chief Financial Officer of Meridian, effective as of February 21, 2022. Prior to joining Meridian, Mr. Kitzmiller served as the Vice President, Chief Accounting Officer and Controller of Hillenbrand, Inc. since November 2019, and served more than two years in senior finance roles at Milacron Holding Corp., as Vice President – Finance and Corporate Controller (April 2019 to November 2019) and as Corporate Controller (September 2017 to April 2019).- Andrew S. Kitzmiller被任命为Meridian的首席财务官，自2022年2月21日起生效。在加入Meridian之前，Kitzmiller先生自2019年11月起担任Hillenbrand公司副总裁、首席会计干事和财务总监，并在Milacron控股公司担任了两年多的高级财务职务，担任副总裁兼财务和公司财务总监（2019年4月至2019年11月）和公司财务总监（2017年9月至2019年4月）。
- Andrew S. Kitzmiller,was appointed as the Chief Financial Officer of Meridian, effective as of February 21, 2022. Prior to joining Meridian, Mr. Kitzmiller served as the Vice President, Chief Accounting Officer and Controller of Hillenbrand, Inc. since November 2019, and served more than two years in senior finance roles at Milacron Holding Corp., as Vice President – Finance and Corporate Controller (April 2019 to November 2019) and as Corporate Controller (September 2017 to April 2019).